2019
DOI: 10.1101/709881
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Bupropion inhibits serotonin type 3AB heteromeric channels at a physiologically relevant concentration

Abstract: Bupropion, a FDA-approved antidepressant and smoking cessation aid, blocks dopamine and norepinephrine reuptake transporters and non-competitively inhibits nicotinic acetylcholine (nACh) and serotonin type 3A (5-HT 3 ) receptors. 5-HT 3 receptors are pentameric ligand-gated ion channels that regulate synaptic activity in the central and peripheral nervous system pre-and postsynaptically. In the present study, we examined and compared the effect of bupropion and its active metabolite hydroxybupropion on homomer… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 69 publications
(121 reference statements)
0
0
0
Order By: Relevance